US study suggests BMS’ cancer drug could target Parkinson’s-causing protein
The progressive neurodegenerative condition affects more than ten million people worldwide
Read More
Tag: Bristol-Myers Squibb
Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation
Treatment involves adults with certain forms of advanced stomach and oesophageal cancer
Read More
Bristol Myers Squibb opens 125-acre biologics campus in Dublin
Facility also includes a cell culture suite, quality control laboratories and technology labs
Read More
Bristol Myers Squibb’s Opdivo recommended by NICE for malignant pleural mesothelioma patients
Armed forces veterans and people who were exposed to asbestos could benefit from the therapy
Read More
Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read More
BMS advances AI-designed drug candidate into development
Option is a collaboration between BMS and AI-driven pharmatech Exscientia
Read More
EMA accepts BMS’ Opdivo application in oesophageal cancer
Phase III trial showed significant survival benefit over chemotherapy alone
Read More
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
First treatment to be approved for UK MPM patients for more than 15 years
Read More
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
Read More
Opdivo combos show OS benefit in advanced oesophageal cancer
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Read More
BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme
BMS will pay Agenus $200m upfront and up to $1.36bn in development, regulatory and commercial milestones
Read More
NICE nod for BMS’ Opdivo in advanced oesophageal cancer
Cost-effectiveness watchdog recommends first immunotherapy for unresectable advanced oesophageal cancer
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
